106 filings
8-K
VYNE
VYNE Therapeutics Inc
29 Feb 24
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
8:12am
8-K
VYNE
VYNE Therapeutics Inc
3 Jan 24
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors
8:15am
8-K
VYNE
VYNE Therapeutics Inc
13 Dec 23
Departure of Directors or Certain Officers
4:00pm
8-K
VYNE
VYNE Therapeutics Inc
13 Nov 23
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:46am
8-K
VYNE
VYNE Therapeutics Inc
30 Oct 23
VYNE Therapeutics Announces Private Placement of $88 Million
7:30am
8-K
ihybacd8g9vrq0j9 4i
14 Aug 23
VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
8:00am
8-K
blckgc4d2ksd8
11 May 23
VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:21pm
8-K
777l zk7gta
1 May 23
Preclinical studies suggest VYN202 has the potential to be the most potent and selective BET inhibitor in development
8:15am
8-K
bjcd 55fyito
9 Mar 23
VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update
4:06pm
8-K
8upmec6t 6a61
28 Feb 23
Entry into a Material Definitive Agreement
4:32pm
8-K
y7kzhcw2jhp
10 Feb 23
Material Modifications to Rights of Security Holders
5:01pm
8-K
sci8q b2grzkaaje
17 Jan 23
Amendments to Articles of Incorporation or Bylaws
5:15pm
8-K
d7l4fz5thhjw67
12 Jan 23
Results of Operations and Financial Condition
5:13pm
8-K
8rh lr7xb3
10 Nov 22
VYNE Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
4:16pm
8-K
6abs5ohso0nkt
30 Aug 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
7et 7qi4a8qbv58l9
12 Aug 22
VYNE Therapeutics Reports Second Quarter 2022 Financial Results
8:15am
8-K
oh5hosb zfc
10 Aug 22
VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
5:01pm
8-K
75yxlj6
27 Jul 22
Regulation FD Disclosure
9:15am
8-K
z33do0en4 ouvv82
17 Jun 22
VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
8:15am
8-K
dgixtwcq lt8
17 May 22
Regulation FD Disclosure
10:01am